Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.71 |
| ▸ | DRD3 | P35462 | 2/20 | 0.71 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.71 |
| ▸ | FYN | P06241 | 1/20 | 0.60 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | THPO | P40225 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6641798 | 0.98 | DRD2 (0.69) | DRD2DRD3OPRK1FYNCA1 | |
| Bromide SCHEMBL8765825 | 0.98 | DRD2 (0.69) | DRD2DRD3OPRK1FYNCA1 | |
| SCHEMBL30697493 | 0.84 | DRD2 (1.00) | DRD2DRD3OPRK1CYP19A1DRD4 | |
| SCHEMBL265949 | 0.84 | DRD2 (1.00) | DRD2DRD3OPRK1CYP19A1DRD4 | |
| SCHEMBL266800 | 0.84 | OPRK1 (1.00) | DRD2DRD3OPRK1CYP19A1DRD4 | |
| SCHEMBL30839518 | 0.84 | DRD2 (1.00) | DRD2DRD3OPRK1CYP19A1DRD4 | |
| SCHEMBL5722322 | 0.84 | DRD2 (1.00) | DRD2DRD3OPRK1CYP19A1DRD4 | |
| SCHEMBL9135070 | 0.84 | DRD2 (1.00) | DRD2DRD3OPRK1CYP19A1DRD4 | |
| Bromide SCHEMBL354286 | 0.82 | DRD2 (0.96) | DRD2DRD3OPRK1DRD4MAPT | |
| Water SCHEMBL9305270 | 0.82 | DRD2 (0.96) | DRD2DRD3OPRK1CYP19A1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101638-B2 | 6-substituted nicotinamide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| US-20090023785-A1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | PEDREGAL-TERCERO CONCEPCION | 2009-01-22 | — | — | US | disclosed |
| US-7399774-B2 | 6-substituted nicotinamide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-07-15 | — | — | US | disclosed |
| EP-1613597-B1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2007-11-07 | — | — | EP | disclosed |
| US-20060205715-A1 | 6-Substituted nicotinamide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY | 2006-09-14 | — | — | US | disclosed |
| EP-1613597-A1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | Eli Lilly and Company (US) | 2006-01-11 | — | — | EP | disclosed |
| CN-1212861-C | Preventives or remedies for myocarditis, dilated cardiomyopathy and cardiac insufficiency containing NF-K B inhibitors as the active ingredient | DAIICHI SUNTORY PHARMACEATICAL (JP) | 2005-08-03 | — | — | CN | disclosed |
| WO-2004080968-A1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2004-09-23 | — | — | WO | disclosed |
| CN-1335777-A | Preventives or remedies for myocarditis, dilated cardiomyopathy and cardiac insufficiency containing NF-K B inhibitors as the active ingredient | SUNTORY LTD (JP) | 2002-02-13 | — | — | CN | disclosed |
| EP-0330380-B1 | NOVEL INDANOXYACETIC ACID DERIVATIVES AND PROCESSES FOR PREPARING THE SAME | TANABE SEIYAKU CO., LTD. (JP) | 1993-06-23 | — | — | EP | disclosed |
| US-4975460-A | INHIBITION OF PLATELET AGGREGATION | TANABE SEIYAKU CO., LTD. (JP) | 1990-12-04 | — | — | US | disclosed |
| EP-0330380-A2 | Novel indanoxyacetic acid derivatives and processes for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 1989-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205715-A1 | 6-Substituted nicotinamide derivatives as opioid receptor antagonists | OPRM1, OPRL1, OPRK1 | DRD2 366/4885DRD3 384/4885OPRK1 3/4885 |
| US-20090023785-A1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRK1, OPRD1 | DRD2 217/4885DRD3 180/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.